OTHER INFORMATION
−Removed: Not applicable .
+Added: 2021 Corporate Performance Goals
+Added: On October 29, 2021, the Compensation Committee approved corporate performance goals for the fiscal year ending December 31, 2021.
+Added: The corporate performance goals, which may be updated at the Board’s discretion during 2021, include:
+Added: goals related to executing our development plan for rNAPc2 (AB201), our clinical product candidate for the treatment of patients with COVID-19;
+Added: goals related to further defining our development plan for Gencaro, our clinical product candidate for the treatment of atrial fibrillation;
+Added: finance and corporate compliance goals.
EXHIBIT INDEX
9 unchanged sentences
Form of Common Stock Certificate .
−Removed: Amendment No.
−Removed: 1 to Capital on Demand TM Sales Agreement, dated April 6, 2021, by and between ARCA biopharma, Inc.
−Removed: and JonesTrading Institutional Services LLC .
−Removed: Employment Agreement, dated April 21, 2021, by and between ARCA biopharma, Inc.
−Removed: Jeff Dekker .
−Removed: Assignment Agreement for Patent Rights, dated July 1, 2021, by and between ARCA biopharma, Inc.
−Removed: and University Medical Center of the Johannes Gutenberg University Mainz .
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .
4 unchanged sentences
Inline XBRL Taxonomy Extension Schema Document (filed electronically herewith)
−Removed: Incorporated by Reference (1)
Inline XBRL Taxonomy Extension Calculation Linkbase Document (filed electronically herewith)
1 unchanged sentence
Inline XBRL Taxonomy Extension Presentation Linkbase Document (filed electronically herewith)
+Added: Incorporated by Reference (1)
Inline XBRL Taxonomy Extension Definition Linkbase Document (filed electronically herewith)
1 unchanged sentence
The SEC file number for all items incorporated by reference herein from reports on Forms 10-K, 10-Q and 8-K is 000-22873.
−Removed: Indicates management contract or compensatory plan or arrangement.
−Removed: Schedules have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K.
−Removed: ARCA agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request;
−Removed: provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule so furnished.
−Removed: Certain portions of the exhibit, identified by the mark, “[*],” have been omitted because such portions contained information that is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
4 unchanged sentences
(Principal Financial and Accounting Officer)
−Removed: August 4, 2021
+Added: November 2, 2021
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.